Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • Log out
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Role of Human Liver Cytochrome P4503A in the Metabolism of Etoricoxib, a Novel Cyclooxygenase-2 Selective Inhibitor

Kelem Kassahun, Ian S. McIntosh, Magang Shou, Deborah J. Walsh, Carey Rodeheffer, Donald E. Slaughter, Leslie A. Geer, Rita A. Halpin, Nancy Agrawal and A. David Rodrigues
Drug Metabolism and Disposition June 2001, 29 (6) 813-820;
Kelem Kassahun
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian S. McIntosh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Magang Shou
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deborah J. Walsh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carey Rodeheffer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donald E. Slaughter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leslie A. Geer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rita A. Halpin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nancy Agrawal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. David Rodrigues
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, was shown to be metabolized via 6′-methylhydroxylation (M2 formation) when incubated with NADPH-fortified human liver microsomes. In agreement with in vivo data, 1′-N′-oxidation was a relatively minor pathway. Over the etoricoxib concentration range studied (1–1300 μM), the rate of hydroxylation conformed to saturable Michaelis-Menten kinetics (apparent K m = 186 ± 84.3 μM; V max = 0.76 ± 0.45 nmol/min/mg of protein; mean ± S.D., n = 3 livers) and yielded a V max/Km ratio of 2.4 to 7.3 μl/min/mg. This in vitroV max/K m ratio was scaled, with respect to yield of liver microsomal protein and liver weight, to obtain estimates of M2 formation clearance (3.1–9.7 ml/min/kg of b.wt.) that agreed favorably with in vivo results (8.3 ml/min/kg of b.wt.) following i.v. administration of [14C]etoricoxib to healthy male subjects. Cytochrome P450 (P450) reaction phenotyping studies—using P450 form selective chemical inhibitors, immunoinhibitory antibodies, recombinant P450s, and correlation analysis with microsomes prepared from a bank of human livers—revealed that the 6′-methyl hydroxylation of etoricoxib was catalyzed largely (∼60%) by member(s) of the CYP3A subfamily. By comparison, CYP2C9 (∼10%), CYP2D6 (∼10%), CYP1A2 (∼10%), and possibly CYP2C19 played an ancillary role. Moreover, etoricoxib (0.1–100 μM) was found to be a relatively weak inhibitor (IC50 > 100 μM) of multiple P450s (CYP1A2, CYP2D6, CYP3A, CYP2E1, CYP2C9, and CYP2C19) in human liver microsomes.

Nonsteroidal anti-inflammatory drugs (NSAIDs1) are widely used for the treatment of pain, inflammation, and fever (Donnelly and Hawkey, 1997; Jouzeau et al., 1997). The mechanism of action of many of these drugs (e.g., meloxicam, lornoxicam, tenoxicam, and indomethacin) is thought to involve the inhibition of COX, a hemeprotein that has been shown to convert arachidonic acid to proinflammatory prostaglandins and their subsequent metabolic products (Wu, 1998). COX behaves as an endoperoxide synthetase, catalyzing the formation of the cyclic endoperoxide prostaglandin G2 from the unesterified precursor fatty acid, and as a peroxidase that converts prostaglandin G2 to prostaglandin H2. Prostaglandin H2 is then converted to other products (e.g., prostaglandin I2 and thromboxane A2) via the action of prostacyclin synthetase and thromboxane synthetase.

COX has been shown to exist in two forms (COX-1 and COX-2). COX-1 is thought to carry out “housekeeping” functions (e.g., cytoprotection of the gastric mucosa and platelet aggregation) and catalyzes the production of prostaglandins under normal physiological conditions. By comparison, COX-2 is normally undetectable in most tissues and is inducible by cytokines, endotoxins, and tumor promotors (Donnelly and Hawkey, 1997; Jouzeau et al., 1997). Since the products of COX-1 are cytoprotective, selective inhibition of COX-2 is anticipated to reduce inflammation without the gastrointestinal side effects characteristic of NSAIDs currently in use (Donnelly and Hawkey, 1997; Jouzeau et al., 1997; Riendeau et al., 1997; Wu, 1998). Therefore, much attention has been focused on the design of potent and selective COX-2 inhibitors (Leblanc et al., 1995, 1999; Penning et al., 1997; Janusz et al., 1998). One such example is etoricoxib (Fig.1), which is under investigation for the treatment of osteoarthritis and rheumatoid arthritis. The drug has been shown to be a potent and selective inhibitor of COX-2 in vitro and exhibits pharmacological activity in vivo (Friesen et al., 1998;Riendeau et al., 2000). In an earlier study, the in vitro metabolites of etoricoxib [5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]-bipyridinyl] were characterized, and preliminary studies with recombinant P450s suggested that multiple P450s were involved in the oxidative metabolism of the drug (Chauret et al., 2001). Although etoricoxib is a low clearance compound (0.8 ml/min/kg), with high oral bioavailability (>80%), it has been shown to undergo extensive biotransformation (>90% of the dose) to metabolites that are detected in urine and feces (R. Halpin and N. Agrawal, unpublished observations). Because it is likely that etoricoxib will be administered with other drugs in a clinical setting, we sought to study the in vitro NADPH-dependent metabolism of [14C]etoricoxib in native human liver microsomes and to identify the P450 forms involved in its metabolism. We also wanted to determine the relevance of the in vitro data to the situation in vivo by determining the metabolite profile of etoricoxib in human urine.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Proposed etoricoxib oxidative pathways.

Materials and Methods

Chemicals.

Unlabeled etoricoxib and [14C]etoricoxib (labeled at the methyl group of the methanesulfonylphenyl substituent; 28 μCi/mg, radiochemical purity >98%) were synthesized at Merck Research Laboratories (West Point, PA, and Rahway, NJ). The 1′-N′-oxide (M1), 6′-hydroxymethyl (M2), and 6′-carboxy (M3) metabolites of etoricoxib were provided by R. Friesen (Merck-Frosst Center for Therapeutic Research, QC, Canada). Ketoconazole, sulfaphenazole, furafylline (Research Biologics, Inc., Natick, MA), and (S)-(+)-mephenytoin (Salford Ultrafine Chemicals and Research, Manchester, UK) were purchased from the sources indicated. Omeprazole sulfone and fluvoxamine were obtained from the Merck compound repository (West Point, PA). All other commercially available reagents and solvents were of either analytical or HPLC grade. Insect cell microsomes (“Supersomes”) containing various individual cDNA-expressed P450 proteins and NADPH-P450 reductase were obtained from GENTEST Corp. (Woburn, MA). Microsomes prepared from cells containing the selectable plasmid vector without cDNA insert, which were essentially devoid of P450 etoricoxib hydroxylase activity, were also obtained from GENTEST. Human liver microsomes (individual organ donor subjects HHM-0228 and HHM-0232; pool of livers HHM-0253) were purchased from The International Institute for the Advancement of Medicine (IIAM, Exton, PA). The microsomes had been characterized with respect to the specific content of total P450 (HHM-0228, 0.66 nmol/mg; HHM-0232, 0.63 nmol/mg; and HHM-0253, 0.54 nmol/mg) and various P450 form selective monooxygenase activities, e.g., CYP3A4/5 selective testosterone 6β-hydroxylase activity (HHM-0228, 5.5 nmol/min/mg; HHM-0232, 3.7 nmol/min/mg; and HHM-0253, 2.9 nmol/min/mg). A bank of fully characterized human liver microsomes (n = 15 different organ donors) was purchased from Xenotech LLC (Kansas City, KS).

Incubation of Etoricoxib with Native Human Liver Microsomes.

In vitro incubations were performed at 37°C in a Dubnoff shaking water bath, using 12 × 75 mm borosilicate glass disposable culture tubes (Machinist et al., 1995; Rodrigues et al., 1996). Briefly, the final assay volume was 0.25–1.0 ml and consisted of the following: 0.1 M potassium phosphate buffer (pH 7.4), magnesium chloride (5 mM), NADP+ (1.0 mM),d-glucose 6-phosphate (10 mM), d-glucose 6-phosphate dehydrogenase (Sigma Type VII, from baker's yeast, 2.0 units/ml), microsomal protein (0.5–2.5 mg/ml), and [14C]etoricoxib (1–1300 μM) dissolved in acetonitrile (<1% v/v, final volume in assay). The reactions were initiated by addition of the NADPH generating system after a 3-min preincubation period (37°C, open to air) and then stopped by addition of 1.5% (v/v) glacial acetic acid in acetontrile:methanol (2:1, v/v). In each case, the sample was centrifuged (2000g, 10 min), and the supernatant was decanted into a clean tube. After evaporation to dryness under nitrogen at 37°C, the dried residue was reconstituted in 0.2 ml of acetonitrile (30%, v/v). An aliquot of sample (0.1 ml) was analyzed by HPLC with radiometric detection.

Kinetic Analysis.

Estimates of apparent K m andV max were obtained by fitting the untransformed data to a one- or two-enzyme model (PCNONLIN version 4.0; Statistical Consultants, Inc., Lexington, KY) using 16 different concentrations of etoricoxib (Rodrigues et al., 1996). Initial kinetic parameter estimates were obtained using EnzymeKinetics (Macintosh version 1.3; Trinity Software, Compton, NH). Data were also analyzed by linear transformation (Eadie-Hofstee plot) to confirm a singleK m model. The in vitro M2formation CLint(V max/K m) was scaled with respect to the yield of microsomal protein (45 mg/g liver) and liver weight (26 g liver/kg of b.wt.). Protein binding in microsomes (f u, inc) was determined at two concentrations of [14C]etoricoxib (5 and 200 μM) with an ultrafiltration technique using the Centrifree Micropartition System (Amicon, Beverly, MA). Drug was incubated with human liver microsomes (1.0 mg protein/ml) at 37°C in 0.1 M potassium phosphate buffer (pH 7.4). At both concentrations of drug, protein binding was low (∼12% bound), and CLint, in vitro was corrected with respect to free fraction (f u, inc = 0.88). Thus, the predicted (free) intrinsic clearance of etoricoxib in vivo (CLint, in vivo(pred); ml/min/kg of b.wt.) was calculated using the following relationship (Obach, 1996; Obach et al., 1997):CLint,in vivo(pred)=CLint,in vitro·(1/fu,inc)·45·26·(1/1000). Equation 1Estimates of CLint, in vivo(pred) were compared with the observed values of CLint in vivo (CLint, in vivo(obs)), where CLint, in vivo(obs) was calculated from i.v. data in humans (etoricoxib CLp = 0.8 ml/min/kg, mean of n = 6 subjects, coefficient of variation = 25%; N. Agrawal unpublished observations; Q h, b = 21 ml/min/kg; f u, p = 0.08; B/P = 0.79) using eq. 2 (Wilkinson, 1987). No unchanged parent drug was detected in the urine of subjects receiving i.v. [14C]etoricoxib (CLr = 0), and the percentage of the etoricoxib dose excreted as M2and M3 in urine and feces was 80% (f m = 0.8):CLint,in vivo=1fu,p·(B/P)·(CLp−CLr)·Qh,b(B/P)·Qh,b−(CLp−CLr)·fm Equation 2

Measurement of P450 Form Selective Activities.

Microsomal samples (Xenotech, LLC) were prepared for incubation and analysis as described previously. The rate of M2 formation, at each concentration of etoricoxib (5 and 200 μM), was correlated with the various P450 monooxygenase activities. These activities (data provided by Xenotech, LLC) included 7-ethoxyresorufinO-deethylase (CYP1A2), coumarin 7-hydroxylase (CYP2A6), Taxol 6-hydroxylase (CYP2C8), tolbutamide methyl-hydroxylase (CYP2C9), (S)-mephenytoin 4′-hydroxylase (CYP2C19), chlorzoxazone 6-hydroxylase (CYP2E1), bufuralol 1′-hydroxylase (CYP2D6), and testosterone 6β-hydroxylase (CYP3A4/5). Correlation coefficients (r) were determined graphically (Machinist et al., 1995;Rodrigues et al., 1996). In each case, the statistical significance of the correlation is denoted by: *p < 0.05, **p < 0.01, and ***p < 0.001 (Student's t test).

P450 Selective Inhibitors.

Inhibition studies with P450 form selective chemical inhibitors were carried out at a final [14C]etoricoxib concentration of 5 μM (<K m) and 200 μM (∼K m). Where possible, mechanism-based inhibitors (e.g., troleandomycin and furafylline), relatively high affinity reversible inhibitors (K i ≤ 1.0 μM), or cosubstrates (K m ≤5.0 μM) were used. Where appropriate, the final concentration of the inhibitor (cosubstrate) exceeded (≥ 10-fold) its apparentK i (Newton et al., 1995; Bourrie et al., 1996; Rodrigues et al., 1996). This ensured maximal inhibition (>80%) of each P450 form ([I]/K i≥10; [S] ≤ K m). In addition, the inhibitors were dissolved in acetonitrile:water (50:50, v/v), in which case the final concentration of acetonitrile in the incubations was kept to a minimum (≤1.0% v/v).

Incubation with Insect Cell Microsomes Containing cDNA-Expressed P450 Forms.

Incubations with [14C]etoricoxib (50 μM) were conducted at 37°C, in 1.5 ml polypropylene centrifuge tubes (final volume of 0.25 ml to 0.6 ml), and were conducted as described for liver microsomes, except that the molarity of phosphate buffer was decreased to 10 mM. Samples were preincubated for 5 min, after which time the reaction was started with the addition of rapidly thawed (37°C) microsomal protein (0.5 mg/ml final concentration). In all cases, the reactions were allowed to proceed for the maximum period of linearity (CYP3A4 + b5, 20 min; CYP1A2, 80 min; CYP2A6, 40 min; CYP2C9*1, 10 min; CYP2C8, 160 min; CYP2C19, 10 min; and CYP2D6, 10 min).

For all P450 proteins tested, the reaction rates (pmol/h/pmol of P450) were normalized (pmol/h/pmol · pmol of P450/mg) with respect to the corresponding nominal (mean) specific content of each P450 in native human liver microsomes (data provided by GENTEST Corp.; CYP3A4, 108 pmol/mg; CYP1A2, 45 pmol/mg; CYP2A6, 68 pmol/mg; CYP2C9, 96 pmol/mg; CYP2C8, 64 pmol/mg; CYP2C19, 19 pmol/mg; and CYP2D6, 10 pmol/mg). The normalized rates (pmol/h/mg) were then added, and the normalized rate for each P450 was expressed as the percentage of the total normalized rate (Rodrigues, 1999).

Apparent K m andV max were determined using an in-house preparation of insect cell microsomes containing cDNA-expressed CYP3A4 (Mei et al., 1999). Incubations were performed in 100 mM potassium phosphate buffer (pH 7.4), as described for native liver microsomes (final concentration of CYP3A4 = 0.3 nmol/ml).

Immunoinhibition Studies.

[14C]Etoricoxib (50 μM) was incubated with a native human liver microsomes (pool of samples HHM-0288, HHM-0232, and HHM-0253) as described previously (0.24 mg protein/ml; 146 pmol of P450/ml). Incubations (final assay volume of 0.25 ml) were performed in the presence of increasing amounts (0–18 mg IgG/nmol of P450) of preimmune sera or anti-CYP3A4 peptide polyclonal antibodies (Wang and Lu, 1997).

HPLC.

Etoricoxib and its metabolites were separated on a reverse-phase C8 (Zorbax Eclipse XDB-C8, 4.6 × 250 mm, 5 μm) column using a Hewlett-Packard HP1100 liquid chromatography system with the column oven temperature set at 40°C. The mobile phase consisted of (A) 20% acetonitrile:80% ammonium acetate (25 mM, pH 7–7.4), and (B) acetonitrile and was programmed to go from 0 to 30% B over 30 min at a flow rate of 1 ml/min. The effluent was monitored by photodiode array detection at 236 and 280 nm, and by an on-line radiometric detector (β-RAM, INUS Systems, Inc., Tampa, FL) using a 3 ml/min flow rate for the scintillation cocktail. Under these conditions, the retention times (±0.5 min) of etoricoxib, M2 (6′-methyl hydroxy metabolite), M1 (1′-N-oxide metabolite), andM3 (6′carboxy metabolite) were 26, 17, 14, and 9 min, respectively.

LC/MS.

Metabolites of etoricoxib were identified by electrospray LC-MS/MS analysis using the Finnigan LCQ mass spectrometer. The spray voltage was held at 4.1 kV, and the capillary temperature and voltage were set at 200°C and 6.0 V, respectively. Samples (microsomal and urine extracts) were dissolved in 30% aqueous acetonitrile and introduced into the mass spectrometer via a Zorbax eclipse XDB-C8 column. A gradient of 25 mM ammonium acetate and acetonitrile was used as the mobile phase. In positive-ion mode MS, the 6′-hydroxymethyl metabolite (M2), yielded an MH+ ion (35Cl) atm/z 375, which upon MS/MS analysis produced intense fragment ions at m/z 357 (MH+-H2O) and 278. Similarly, the N-oxide metabolite (M1) yielded an MH+ ion at m/z 375 and produced ions at m/z 357, 296, and 278. The MS/MS spectrum (precursor m/z 389, MH+) of the carboxyl metabolite (M3) exhibited intense ions at m/z 343, 328, and 280. Both the product ion spectra and HPLC retention times of the microsomal and urinary metabolites were similar to those obtained from samples of authentic standards and confirmed earlier findings (Chauret et al., 2001).

Effect of Etoricoxib on P450-Catalyzed Monooxygenase Activities in Native Human Liver Microsomes.

Etoricoxib (0.1, 1.0, 10, and 100 μM) was incubated with human liver microsomes, and its effect on various P450 form selective monooxygenase activities was determined. Activities (phenacetinO-deethylase, CYP1A2; diclofenac 4′-hydroxylase, CYP2C9; (S)-(+)-mephenytoin 4′hydroxylase, CYP2C19; bufuralol 1′-hydroxylase, CYP2D6; chlorzoxazone 6-hydroxylase, CYP2E1; and testosterone 6β-hydroxylase, CYP3A4/5) were measured using standard incubation protocols (Newton et al., 1995; Bourrie et al., 1996;Rodrigues et al., 1996). The following substrate concentrations were used: phenacetin, 25 μM; diclofenac, 10 μM; mephenytoin, 40 μM; bufuralol, 5 μM; chlorzoxazone, 20 μM; and testosterone, 75 μM. For the purposes of comparison, positive control inhibitors were run in parallel (fluvoxamine, CYP1A2; sulfaphenazole, CYP2C9; omeprazole sulfone, CYP2C19; quinidine, CYP2D6; 4-methylpyrazole, CYP2E1; and ketoconazole, CYP3A4/5).

Analysis of Human Urine.

Six healthy male subjects received an i.v. (25 mg, 100 μCi) dose of [14C]etoricoxib. The dose was administered in citrate-buffered saline (pH 3.6, 0.75 mg/ml) as a 15-min infusion. Urine (0–2, 2–4, 4–6, 6–9, 9–12, 12–18, and 18–24 h postdose) was collected and stored frozen at −20°C. Prior to analysis, the urine was thawed at room temperature, and aliquots from each time interval were combined in proportion to their respective volumes to produce a representative 0–24 h sample for each subject. Aliquots (0.2 ml) were taken for liquid scintillation counting. A second aliquot (5 ml) was transferred to glass centrifuge tubes, and trifluoroacetic acid (15 μl) was added to acidify the samples to approximately pH 3. Acetonitrile (20 ml) was added with mixing, and particulate material was removed by centrifugation (2000 g, 10 min). The supernatants were transferred to 50-ml glass tubes, and solvent was removed in a centrifugal vacuum concentrator (Speed-Vac, Savant, Holbrook, NY). The residues were reconstituted in mobile phase and analyzed by HPLC with radiometric detection as described previously.

Results

P450-Dependent Metabolism of Etoricoxib.

A typical radiochromatograph of the supernatant following incubation of [14C]etoricoxib with NADPH-fortified human liver microsomes is presented in Fig. 2A. After incubation, one major metabolite peak was observed (retention time of 17 min), which coeluted with authentic M2 standard and was identified by LC/MS as the 6′-methyl hydroxy metabolite of etoricoxib. Omission of the NADPH generating system completely abolished the hydroxylation reaction by human liver microsomes, indicating that metabolite formation was enzymatic and NADPH-dependent. By comparison, low levels of the 1′-N-oxide metabolite (M1) were detected in the presence of the NADPH generating system (Fig. 2A). In addition, no secondary metabolism was detected, although the 6′-carboxy metabolite (M3) accounted for the majority of the radioactivity in human urine (Fig. 2B) and feces (R. Halpin unpublished observations).

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2

Representative HPLC radiograms of (A) [14C]etoricoxib after incubation with human liver microsomes; and (B) human urine (0–24 h) after administration of [14C]etoricoxib (approximately 65% of the dosed carbon-14 radioactivity is excreted in urine).

M2, M1, and M3 represent 6′-methylhydroxy, 1′-N′-oxide, and 6′-carboxy metabolites of etoricoxib, respectively.

In a panel of human liver microsomes (n = 15 different organ donors), the interindividual variability in the rate of 6′-methyl hydroxylation ranged from 3.5-fold at a final etoricoxib concentration of 200 μM (range 105–372 pmol/min/mg; mean of 203 pmol/min/mg) to 9.5-fold at a final etoricoxib concentration of 5 μM (range 3.2–18.5 pmol/min/mg; mean of 9.5 pmol/min/mg).

Reaction Kinetics and Prediction of Intrinsic Clearance.

Under linear reaction conditions (1–1.5 mg protein/ml; 30-min incubation), the 6′-methyl hydroxylation of etoricoxib (1.0–1300 μM) in native liver microsomes conformed to singleK m Michaelis-Menten kinetics (Fig.3A). Nonlinear transformation of the data yielded a mean apparent K m andV max of 186 μM and 0.76 nmol/min/mg (mean of n = 3 different microsomal preparations), respectively (Table 1).

Figure 3
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3

Effect of substrate concentration on the rate of hydroxylation of etoricoxib.

Representative Michaelis plots showing metabolism in the presence of native human liver microsomes (HHM-0253) (A) and cDNA-expressed CYP3A4 (B). Inset, Eadie-Hofstee plot of the data. For native human liver microsomes parameter data are shown in Table 1. The following estimates of apparent K m andV max were obtained with insect microsomes containing cDNA-expressed CYP3A4 (S.E. of the parameter estimate in parentheses): K m = 201 (±12) μM,V max = 1.86 (±0.05) nmol/min/nmol of CYP3A4, andV max/K m = 9.3 μl/min/nmol of CYP3A4.

View this table:
  • View inline
  • View popup
Table 1

Summary of the apparent kinetic parameters for the hydroxylation of etoricoxib by native human liver microsomes

The in vitro intrinsic clearance (V max/K m ratio) was scaled, with respect to yield of microsomal protein and liver weight, and yielded a value of 3.1 to 9.7 ml/min/kg of b.wt. as the formation clearance of M2. Similarly, the in vivo intrinsic clearance was estimated to be 8.3 ml/min/kg, using i.v. data obtained from six subjects.

Correlation Studies.

Etoricoxib (5 and 200 μM) hydroxylation was significantly correlated (r = 0.80–0.89; p < 0.001;n = 15) with CYP3A4/5-selective testosterone 6β-hydroxylase activity in the bank of liver microsomes. By comparison (Table 2), the correlation with 7-ethoxyresorufin O-deethylase (CYP1A2), (S)-(+)-mephenytoin 4′-hydroxylase (CYP2C19), tolbutamide methyl hydroxylase (CYP2C9), chlorzoxazone 6-hydroxylase (CYP2E1), and bufuralol 1′-hydroxylase (CYP2D6) activity was relatively weak (r ≤ 0.47). It is important to note that, while the correlations with CYP2A6-selective coumarin hydroxylase (r = 0.71; p < 0.01) and CYP2C8-selective Taxol 6-hydroxylase (r = 0.72;p < 0.01) activities are significant, both activities correlated with the rates of testosterone 6β–hydroxylation (r ≅ 0.79; p < 0.001) and, because of coregression, correlation with etoricoxib hydroxylation would be expected. Moreover, correlation of etoricoxib hydroxylase activity with these enzymes did not improve in the presence of CYP3A4 monoclonal antibody (data not shown). Overall, the data indicate that CYP3A subfamily member(s) play a major role in the formation of M2over a relatively wide etoricoxib concentration range (5–200 μM). In agreement, the correlation of M2 formation at two different concentrations of etoricoxib (5 μM versus 200 μM) was significant (r = 0.81; p < 0.001), also suggesting that the same P450 form(s) catalyzed the reaction over the etoricoxib concentration range studied.

View this table:
  • View inline
  • View popup
Table 2

Correlation of various P450-selective monooxygenase activities with the hydroxylation of etoricoxib (5 and 200 μM) in a panel of human liver microsomes

Chemical Inhibition Studies.

Ketoconazole (2.0 μM) and troleandomycin, both selective inhibitors of CYP3A in native human liver microsomes, were shown to effectively decrease (65–70%) the rate of M2 formation at two concentrations (5 and 200 μM) of etoricoxib (Fig.4). By comparison, chemical inhibitors selective for other P450s were relatively weak, although some inhibition (∼10%) was observed in the presence of furafylline (CYP1A2-selective), sulfaphenazole (CYP2C9-selective), or quinidine (CYP2D6-selective). In agreement with correlation studies, these data suggested that the 6′-methyl hydroxylation of etoricoxib was primarily catalyzed by member(s) of the CYP3A subfamily, although other P450s (∼10% each), such as CYP1A2, CYP2D6, and CYP2C9 also played a role. When sulfaphenazole (5 μM), ketoconazole (2 μM), and quinidine (10 μM) were coincubated, M2 formation was inhibited by approximately 84 ± 5.7% (data not shown), suggesting that CYP3A, CYP2C9, and CYP2D6 accounted for the majority of the oxidative (NADPH-dependent) metabolism of etoricoxib in native human liver microsomes.

Figure 4
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4

Inhibition of etoricoxib metabolism in the presence of human liver microsomes by a series of P450 form selective inhibitors.

Data represent mean ± S.D. of three different microsomal preparations (subject HHM-0228, subject HHM-0232, and pool HHM-0253). Inhibition data are expressed relative to activities measured in the presence of solvent alone. Proposed P450 form selectivity of the inhibitors: furafylline (FURA, 30 μM), CYP1A2; ketoconazole (KTZ, 2 μM), CYP3A; troleandomycin (TAO, 50 μM), CYP3A; sulfaphenazole (SLF, 5 μM), CYP2C9; quinidine (QND, 10 μM), CYP2D6; 4-methylpyrazole (4MP, 50 μM), CYP2E1; coumarin (COU, 200 μM), CYP2A6. Furafylline or troleandomycin was preincubated with human liver microsomes (15 min at 37°C) prior to the addition of [14C]etoricoxib.

In a separate series of experiments, the inhibitory effect of troleandomycin was confirmed with the bank of human liver microsomes (Fig. 5). Inhibition in the presence of troleandomycin (mean ± S.D. = 68 ± 13.4; n= 16 subjects), which varied from 40% (subject 24) to 90% (subject 2), correlated (r = 0.87; p < 0.001) with the levels of CYP3A (testosterone 6β-hydroxylase) activity (data not shown). Despite a lower contribution from CYP3A, other P450s (e.g., CYP2C9, CYP2D6, or CYP1A2) did not contribute to more than 17% of the etoricoxib 6′-methyl hydroxylase activity in microsomes of subject 24 (data not shown).

Figure 5
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5

Testosterone 6β-hydroxylase activity (A) and inhibition of etoricoxib hydroxylase activity by troleandomycin (B) in a panel of human liver microsomes.

Troleandomycin (50 μM) was incubated with microsomal protein (1.0 mg/ml) as described in Fig. 4. Etoricoxib hydroxylase activity was assessed at a final etoricoxib concentration of 50 μM.

Immunoinhibition Studies with Native Human Liver Microsomes.

To confirm the P450 reaction phenotyping results obtained with chemical inhibitors and cDNA-expressed P450s, [14C]etoricoxib (50 μM) was incubated with native human liver microsomes in the absence and presence of immunoinhibitory anti-CYP3A4 peptide polyclonal antibodies. The anti-CYP3A4 antibody preparation has been shown to be highly selective for CYP3A4-catalyzed reactions in native human liver microsomes (Wang and Lu, 1997), and the results with etoricoxib indicated that the majority (∼60%) of the 6′-methyl hydroxylase activity was attributable to CYP3A4 (Fig. 6).

Figure 6
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 6

Effect of increasing concentrations of anti-CYP3A4 peptide or preimmune sera on the rate of etoricoxib hydroxylation in pooled native human liver microsomes.

The experiment was performed with a pool of microsomes, prepared by combining samples HHM-0228, HHM-0232, and HHM-0253.

Metabolism by cDNA-Expressed P450 Forms.

Of the P450 forms tested, CYP3A4 (20 pmol/h/pmol of P450), CYP2D6 (95 pmol/h/pmol of P450), and CYP2C19 (16 pmol/h/pmol of P450) exhibited high rates of hydroxylase activity (Table3). By comparison, the rate of hydroxylation in the presence of cDNA-expressed CYP1A2, CYP2A6, CYP2C8, CYP2C9, and CYP2E1 was low (≤2.3 pmol/h/pmol of P450). No activity was detected in (control) microsomes prepared from insect cells containing the selectable plasmid vector without cDNA insert (data not shown).

View this table:
  • View inline
  • View popup
Table 3

Metabolism of etoricoxib in the presence of insect cell microsomes containing various cDNA-expressed P450 proteins

To obtain meaningful information, the turnover rates obtained with the various cDNA-expressed P450 proteins were normalized with respect to the nominal abundance of each P450 protein in native human liver microsomes (Shimada et al., 1994; Lasker et al., 1998; Rodrigues, 1999). It is evident from the data presented in Table 3 that the hydroxylation of etoricoxib is largely mediated by CYP3A4 (∼60%), whereas a lesser contribution is made by other P450s, such as CYP2C9, CYP2D6, and CYP2C19. In agreement, etoricoxib hydroxylation catalyzed by insect cell microsomes containing recombinant CYP3A4 was characterized by an apparent K m (201 μM) similar to that obtained with native liver microsomes (Fig. 3). If theV max (1.9 nmol/min/nmol of CYP3A4) is normalized with respect to the mean specific content of CYP3A4 (∼0.1 nmol/mg) in a bank of native human liver microsomes (Shimada et al., 1994), this yields a predicted V max of 0.19 nmol/min/mg in human liver microsomes. As shown in Table 1, this value is very close to the V max obtained with the pool of native human liver microsomes (sample HHM-0253,V max = 0.27 nmol/min/mg; 0.16 nmol/min/mg, when adjusted for the contribution of CYP3A, i.e.,V max · f m, CYP3A4 = 0.27 · 0.6).

Effect of Etoricoxib on P450 Form Selective Monooxygenase Activities in Native Human Liver Microsomes.

The inhibitory potential of etoricoxib (0.1–100 μM) toward six human liver P450 activities was evaluated. In all cases, etoricoxib was found to be a relatively weak inhibitor (IC50 > 100 μM). Data obtained with positive control inhibitors showed that incubation conditions were suitable for generating inhibition. IC50 values obtained with positive controls were as follows: quinidine (bufuralol 1′-hydroxylase), IC50 = 0.8 μM; fluvoxamine (phenacetinO-deethylase), IC50 = 0.7 μM; sulfaphenazole (diclofenac 4′-hydroxylase), IC50= 0.6 μM; omeprazole sulfone (mephenytoin 4′-hydroxylase), IC50 = 22 μM; 4-methylpyrazole (chlorzoxazone 6-hydroxylase), IC50 < 0.1 μM; and ketoconazole (testosterone 6β-hydroxylase), IC50 < 0.1 μM.

Discussion

The results of these studies demonstrate that etoricoxib undergoes P450-dependent oxidation and that 6′-methyl hydroxylation represents the major metabolic pathway in NADPH-fortified human liver microsomes (Fig. 2A). By comparison, 1′-N-oxidation to M1 is a relatively minor pathway that agrees with previously reported data (Chauret et al., 2001). The C-oxidation of etoricoxib (to the 6′-carboxy metabolite M3) is the predominant pathway in vivo (Fig. 2B) and suggests that generation of M3 (retention time ∼10 min) in vitro requires the presence of cytosolic enzyme(s). In fact, M3 was shown to be formed by human liver S9 fraction in the presence of NAD+ (data not shown).

Because etoricoxib is extensively metabolized in humans (>90% of the dose), an attempt was made to predict the CLint,in vivo, based on estimates of apparentK m and V max in vitro (Table 1). The CLint, in vitro obtained with human liver microsomes was scaled (Obach et al., 1997) to yield a predicted CLint, in vivo of 3.1 (HHM-0253) to 9.7 (HHM-0228) ml/min/kg. These values compare favorably with the observed CLint, in vivo (8.3 ml/min/kg; mean ofn = 6 subjects; coefficient of variation = 25%; N. Agrawal unpublished results) calculated from the i.v. data (eq. 2).

In human liver microsomes, the 6′-methyl hydroxylation of etoricoxib was characterized as a relatively high apparentK m process (∼0.2 mM), a result that agrees well with earlier data (Chauret et al., 2001) and that has two clinical implications. First, etoricoxib would be expected to exhibit linear pharmacokinetics, which is in agreement with recent findings (N. Agrawal, unpublished observations). Second, one would expect etoricoxib (plasma C max in humans ≤3 μg/ml; ≤8 μM) to be a weak competitive inhibitor of hepatic CYP3A4.

Several lines of evidence (e.g., correlation analysis, P450 form selective inhibitors, and cDNA-expressed P450 proteins) have demonstrated that member(s) of the CYP3A subfamily, most likely CYP3A4, is (are) the principal human liver microsomal enzyme(s) involved in the hydroxylation of etoricoxib. In fact, data obtained with a bank of liver microsomes (n = 16 different organ donors) suggested that the contribution of CYP3A varied from 40% to 90% (mean ± S.D. = 68 ± 13.4%; Fig. 5), which was in agreement with the results obtained with a pool of human liver microsomes (Fig.4). However, it was not possible to evaluate the role of CYP3A5 (versus CYP3A4), because no attempt was made to measure the level of this enzyme in the microsomes used in this study, although the antipeptide antibody used for immunoinhibition studies has been shown to be selective (versus CYP3A5) for CYP3A4 (Wang and Lu, 1997).

Although the data point to a major role for CYP3A, results obtained with P450 form selective chemical inhibitors and recombinant proteins indicate that a number of other P450s (CYP2D6, CYP2C9, CYP1A2, and possibly CYP2C19) more or less equally contribute to the remainder (∼40%) of the 6′-methyl hydroxylase activity in native human liver microsomes. Even when the contribution of CYP3A is relatively low, as in subject 24 (Fig. 5), CYP2D6, CYP2C9, or CYP1A2 do not contribute to more than 17% of the metabolism of etoricoxib (data not shown).

Thus, the P450 reaction phenotype of etoricoxib is rather unique and differs from that of other COX inhibitors, such as celecoxib, meloxicam, lornoxicam, ibuprofen, flurbiprofen, and indomethacin. All of these drugs are extensively metabolized in vivo and are primarily (≥80%) metabolized (K m ≤ 50 μM) by a single P450 form (CYP2C9) in human liver microsomes (Bonnabry et al., 1996; Tracy et al., 1996; Hamman et al., 1997; Chesne et al., 1998;Nakajima et al., 1998; Tang et al., 2000).

For etoricoxib, the clinical relevance of the in vitro P450 reaction phenotype described herein will ultimately depend upon the fraction of the dose that is metabolized via 6′-methyl hydroxylation, which has been estimated to be ∼80% (based on urinary and fecal profiles of subjects dosed with [14C]etoricoxib; R. Halpin, unpublished observations). The results of this study indicate that CYP3A4 accounts for 40 to 90% of the total 6′-methyl hydroxylase activity in human liver microsomes, which implies that approximately 30 to 70% of the dose would be cleared by the enzyme (f m, CYP3A ≈ 0.3–0.7) in vivo. Therefore, it is possible that the area under the curve of etoricoxib would be relatively refractory to the effects of CYP3A4 inhibitors (≤3-fold increase) and inducers (≤60% decrease) (Rodrigues and Wong, 1997).

Interestingly, despite the fact that multiple P450 forms were shown to catalyze the 6′-methyl hydroxylation of etoricoxib (1–1300 μM), the data obtained with native human liver microsomes were adequately described by a single K m model (Fig. 3A). This finding indicates that CYP2C9, CYP2C19, CYP1A2, CYP2D6, and CYP3A4 are likely to be characterized by similar apparentK m values. As expected, CYP3A4 predominates by virtue of its high abundance in the liver (Shimada et al., 1994). Although CYP2C9, CYP2C19, and CYP2D6 are known to be polymorphically expressed (Bertilsson, 1995; Guengerich, 1995; Nasu et al., 1997; Ruas and Lechner, 1997), each enzyme plays a relatively minor role (≤10%) in the metabolism of etoricoxib. Therefore, the pharmacokinetic profile of etoricoxib is not expected to cosegregate with these polymorphisms.

In conclusion, etoricoxib is metabolized via 6′-methyl hydroxylation in human liver microsomes. The reaction is catalyzed by a number of P450 forms, although CYP3A4 accounts for the majority (40–90%) of the activity. The remainder of the activity is equally divided between a number of other P450s (e.g., CYP2D6, CYP2C9, CYP1A2, and possibly CYP2C19). In this regard, the P450 reaction phenotype of etoricoxib is unique and differs from that of other COX inhibitors.

Acknowledgments

We thank Dr. Dennis Dean (Radiosynthesis Group, Drug Metabolism Department, Merck Research Laboratories, Rahway, NJ) for synthesis of [14C]etoricoxib and Dr. T. Prueksaritanont (Drug Metabolism Department, Merck Research Laboratories, West Point, PA) for assistance with the PCNONLIN analysis. In addition, we are grateful to Dr. Regina Wang (Drug Metabolism Department, Merck Research Laboratories, Rahway, NJ) for providing the preparation of anti-CYP3A4 peptide polyclonal antibodies.

Footnotes

  • Send reprint requests to: Dr. Kelem Kassahun, Department of Drug Metabolism, Merck Research Laboratories, Sumneytown Pike, P.O. Box 4, WP75A-203, West Point, PA 19486-0004. E-mail:kelem_kassahun{at}merck.com

  • 1 Abbreviations used are: NSAID, nonsteroidal anti-inflammatory drug; COX, cyclooxygenase; P450, cytochrome P450; HPLC, high-performance liquid chromatography;K m, apparent Michaelis constant,V max, maximal initial reaction velocity; CLint, intrinsic clearance (V max/K m) in vitro (CLint, in vitro) or in vivo (CLint, in vivo); f u, p, fraction of drug unbound in plasma; f u, inc, fraction of drug unbound in the in vitro incubation (e.g., microsomes); CLp, plasma clearance after i.v. dosing; CLr, renal clearance;Q h, b, hepatic blood flow; B/P, blood-to-plasma ratio; f m, fraction of etoricoxib dose excreted in urine and feces as M2 and M3;f m,CYP, fraction of metabolism catalyzed by P450; LC/MS, liquid chromatography/mass spectrometry; MS, mass spectrometry.

    • Received October 19, 2000.
    • Accepted February 9, 2001.
  • The American Society for Pharmacology and Experimental Therapeutics

References

  1. ↵
    1. Bertilsson L
    (1995) Geographical/interracial differences in polymorphic drug oxidation: current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 29:192–209.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Bonnabry P,
    2. Leemann T,
    3. Dayer P
    (1996) Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Eur J Clin Pharmacol 49:305–308.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Bourrie M,
    2. Meunier V,
    3. Berger Y,
    4. Fabre G
    (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277:321–332.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Chauret N, Yergey JA, Brideau C, Freisen RW, Mancini J, Riendeau D, Silva J, Styhler A, Trimble LA and Nicoll-Griffith DA (2001) In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663). Bioorg Med Chem Lett, in press..
  5. ↵
    1. Chesne C,
    2. Guyomard C,
    3. Guillouzo A,
    4. Schmid J,
    5. Ludwig E,
    6. Sauter T
    (1998) Metabolism of meloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotica 28:1–13.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Donnelly MT,
    2. Hawkey CJ
    (1997) Review article: COX-II inhibitors—a new generation of safer NSAIDS? Aliment Pharmacol Ther 11:227–236.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Friesen RW,
    2. Brideau C,
    3. Chan CC,
    4. Charleson S,
    5. Deschenes D,
    6. Dube D,
    7. Ethier D,
    8. Fortin R,
    9. Gauthier JY,
    10. Girard Y,
    11. et al.
    (1998) 2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett 8:2777–2782.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Pacifici GM,
    2. Fraccia GN
    1. Guengerich FP
    (1995) Cytochrome P450 of human liver. Classification and activity profiles of the major enzymes. in Advances in Drug Metabolism in Man, eds Pacifici GM, Fraccia GN (European Commission, Brussels, Belgium), pp 181–231.
  9. ↵
    1. Hamman MA,
    2. Thompson GA,
    3. Hall SD
    (1997) Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem Pharmacol 54:33–41.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Janusz JM,
    2. Young PA,
    3. Ridgeway JM,
    4. Scherz MW,
    5. Enzweiler K,
    6. Wu LI,
    7. Gan L,
    8. Darolia R,
    9. Matthews RS,
    10. Hennes D,
    11. et al.
    (1998) New cyclooxygenase-2/5-lipoxygenase inhibitors. 1. 7-tert-Butyl-2,3-dihydro-3,3-dimethyl- benzofuran derivatives as gastrointestinal safe anti-inflammatory and analgesic agents: discovery and variation of the 5-keto substituent. J Med Chem 41:1112–1123.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Jouzeau JY,
    2. Terlain B,
    3. Abid A,
    4. Nedelec E,
    5. Netter P
    (1997) Cyclo-oxygenase isoenzymes: how recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs 53:563–582.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Lasker JM,
    2. Wester MR,
    3. Aramsombatdee E,
    4. Raucy JL
    (1998) Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide. S-mephenytoin and omeprazole hydroxylations. Arch Biochem Biophys 353:16–28.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Leblanc Y,
    2. Gauthier JY,
    3. Ethier D,
    4. Guay J,
    5. Mancini J,
    6. Riendeau D,
    7. Tagari P,
    8. Vickers P,
    9. Wong E,
    10. Prasit P
    (1995) Synthesis and biological evaluation of 2,3-diarylthiophenes as selective COX-2 and COX-1 inhibitors. Bioorg Med Chem Lett 5:2123–2128.
    OpenUrlCrossRef
  14. ↵
    1. Leblanc Y,
    2. Roy P,
    3. Boyce S,
    4. Brideau C,
    5. Chan CC,
    6. Charleson S,
    7. Gordon R,
    8. Grimm E,
    9. Guay J,
    10. Leger S,
    11. et al.
    (1999) SAR in the alkoxy lactone series: the discovery of DFP, a potent and orally selective COX-2 inhibitor. Bioorg Med Chem Lett 9:2207–2212.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Machinist JM,
    2. Mayer MD,
    3. Shet MS,
    4. Ferrero JL,
    5. Rodrigues AD
    (1995) Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193. Drug Metab Dispos 23:1163–1174.
    OpenUrlAbstract
  16. ↵
    1. Mei Q,
    2. Tang C,
    3. Assang C,
    4. Lin Y,
    5. Slaughter D,
    6. Rodrigues AD,
    7. Baillie TA,
    8. Rushmore TH,
    9. Shou M
    (1999) Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism. J Pharmacol Exp Ther 291:749–759.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Nakajima M,
    2. Tsuyoshi I,
    3. Shimada N,
    4. Tokudome S,
    5. Yamamoto T,
    6. Kuroiwa Y
    (1998) Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes. Drug Metab Dispos 26:261–266.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Nasu K,
    2. Kubota T,
    3. Ishizaki T
    (1997) Genetic analysis of CYP2C9 polymorphism in Japanese population. Pharmacogenetics 7:405–409.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Newton DJ,
    2. Wang RW,
    3. Lu AYH
    (1995) Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154–158.
    OpenUrlAbstract
  20. ↵
    1. Obach RS
    (1996) The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations. Drug Metab Dispos 24:1047–1049.
    OpenUrlPubMed
  21. ↵
    1. Obach RS,
    2. Baxter JG,
    3. Liston TE,
    4. Silber BM,
    5. Jones BC,
    6. MacIntyre F,
    7. Rance DJ,
    8. Wastall P
    (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46–58.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Penning TD,
    2. Talley JJ,
    3. Bertenshaw SR,
    4. Carter JS,
    5. Collins PW,
    6. Docter S,
    7. Graneto MJ,
    8. Lee LF,
    9. Malecha JW,
    10. et al.
    (1997) Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-yl]benzenesulfonamide (SC-58635, celecoxib). J Med Chem 40:1347–1365.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Riendeau D,
    2. Charleson S,
    3. Cromlish W,
    4. Mancini JA,
    5. Wong E,
    6. Guay J
    (1997) Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Can J Physiol Pharmacol 75:1088–1095.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Riendeau D.,
    2. Percival MD,
    3. Brideau C,
    4. Charleson S,
    5. Dubé D,
    6. Ethier D,
    7. Falgueyret JP,
    8. Friesen RW,
    9. Gordon R,
    10. Greig G,
    11. et al.
    (2000) Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 296:558–566.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Rodrigues AD
    (1999) Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57:465–480.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Rodrigues AD,
    2. Kukulka MJ,
    3. Roberts EM,
    4. Ouellet D,
    5. Rodgers TR
    (1996) [O-Methyl 14C]naproxen O-demethylase activity in human liver microsomes: evidence for the involvement of cytochromes P4501A2 and P4502C9/10. Drug Metab Dispos 24:126–136.
    OpenUrlAbstract
  27. ↵
    1. Rodrigues AD,
    2. Wong SL
    (1997) Application of human liver microsomes in metabolism-based drug-drug interactions: in vitro-in vivo correlations and the Abbott Laboratories experience. Adv Pharmacol 43:65–101.
  28. ↵
    1. Ruas JL,
    2. Lechner MC
    (1997) Allele frequency of CYP2C19 in a Portuguese population. Pharmacogenetics 7:333–335.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Shimada T,
    2. Yamazaki H,
    3. Mimura M,
    4. Inui Y,
    5. Guengerich FP
    (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–423.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Tang C,
    2. Shou M,
    3. Mei Q,
    4. Rushmore TH,
    5. Rodrigues AD
    (2000) Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther 298:453–459.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Tracy TS,
    2. Marra C,
    3. Wrighton SA,
    4. Gonzalez FJ,
    5. Korzekwa KR
    (1996) Studies of flurbiprofen 4′-hydroxylation: additional evidence suggesting the sole involvement of cytochrome P450 2C9. Biochem Pharmacol 52:1305–1309.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Wang RW,
    2. Lu AYH
    (1997) Inhibitory anti-peptide antibody against human CYP3A4. Drug Metab Dispos 25:762–767.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Wilkinson GR
    (1987) Clearance approaches in pharmacology. Pharmacol Rev 39:1–47.
    OpenUrlPubMed
  34. ↵
    1. Wu KKY
    (1998) Biochemical pharmacology of nonsteroidal anti-inflammatory drugs. Biochem Pharmacol 55:543–547.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 29 (6)
Drug Metabolism and Disposition
Vol. 29, Issue 6
1 Jun 2001
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Role of Human Liver Cytochrome P4503A in the Metabolism of Etoricoxib, a Novel Cyclooxygenase-2 Selective Inhibitor
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Role of Human Liver Cytochrome P4503A in the Metabolism of Etoricoxib, a Novel Cyclooxygenase-2 Selective Inhibitor

Kelem Kassahun, Ian S. McIntosh, Magang Shou, Deborah J. Walsh, Carey Rodeheffer, Donald E. Slaughter, Leslie A. Geer, Rita A. Halpin, Nancy Agrawal and A. David Rodrigues
Drug Metabolism and Disposition June 1, 2001, 29 (6) 813-820;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Role of Human Liver Cytochrome P4503A in the Metabolism of Etoricoxib, a Novel Cyclooxygenase-2 Selective Inhibitor

Kelem Kassahun, Ian S. McIntosh, Magang Shou, Deborah J. Walsh, Carey Rodeheffer, Donald E. Slaughter, Leslie A. Geer, Rita A. Halpin, Nancy Agrawal and A. David Rodrigues
Drug Metabolism and Disposition June 1, 2001, 29 (6) 813-820;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Proteomic Assessment of a Preclinical Model of Preeclampsia
  • Sex- and lifestyle-related factors affect hepatic CYP levels
  • CYP3A-mediated oxidation of DABE and BIBR0951
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics